Cover Image
Market Research Report

Europe Immunosuppressant Drugs Market Forecast 2019-2028

Published by Inkwood Research Product code 939707
Published Content info 114 Pages
Delivery time: 2-3 business days
Price
Back to Top
Europe Immunosuppressant Drugs Market Forecast 2019-2028
Published: June 1, 2020 Content info: 114 Pages
Description

KEY FINDINGS

The Europe immunosuppressant drugs market is projected to register a CAGR of 4.06% during the forecast period. There has been a considerable increase in R&D activities for drug development, along with the launch of new drugs, resulting in immense market expansion opportunities for market growth. The key players are incorporating key development strategies for introducing new immunosuppressants. The increasing demand for immunosuppressant drugs in the pharmaceutical sector fuels market growth, along with rising investment by the European Union for R&D in the healthcare sector.

MARKET INSIGHTS

The Europe immunosuppressant drugs market growth analysis entails market evaluation of Italy, France, Germany, Poland, Russia, Belgium, the United Kingdom, and the rest of Europe. In Germany, organ donations are considerably low. There are more than 9000 people on the organ waiting list. An opt-out donor scheme has been proposed where the citizen would be automatically registered in the donor list. At the same time, they have the choice of opting out at any time. The doctors are obligated to consult with the family prior to removing the organs of a deceased person. France, too, has a rule where every citizen becomes an organ donor until they decide to opt-out. Autoimmune diseases are the most common disease in the country, which leads to increased demands for immunosuppressant drugs for the treatment of the disease. Such factors are estimated to impact market growth.

COMPETITIVE INSIGHTS

Some of the leading companies establishing their presence in the market are Cipla Ltd, F Hoffmann-La Roche Ag, GlaxoSmithKline Plc, Intas Pharmaceuticals Ltd (Accord Healthcare Ltd), Janssen Pharmaceuticals NV (Johnson & Johnson), etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
Product Code: 31798

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. DEVELOPMENT OF IMMUNOSUPPRESSANT DRUGS
  • 3.2. MARKET DEFINITION
  • 3.3. KEY DRIVERS
    • 3.3.1. INCREASE IN THE NUMBER OF AUTOIMMUNE DISORDERS
    • 3.3.2. RISE IN ORGAN TRANSPLANTATION
    • 3.3.3. GROWTH IN THE PHARMACEUTICAL INDUSTRY
  • 3.4. KEY RESTRAINTS
    • 3.4.1. SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
    • 3.4.2. LACK OF AWARENESS ABOUT ORGAN DONATION

4. KEY ANALYTICS

  • 4.1. KEY INVESTMENT INSIGHTS
  • 4.2. PORTER'S FIVE FORCE ANALYSIS
    • 4.2.1. BUYER POWER
    • 4.2.2. SUPPLIER POWER
    • 4.2.3. SUBSTITUTION
    • 4.2.4. NEW ENTRANTS
    • 4.2.5. INDUSTRY RIVALRY
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE

5. MARKET BY DISTRIBUTION CHANNEL

  • 5.1. HOSPITAL PHARMACIES
  • 5.2. RETAIL PHARMACIES
  • 5.3. ONLINE PHARMACIES

6. MARKET BY END-USER

  • 6.1. ORGAN TRANSPLANTATION
  • 6.2. AUTOIMMUNE DISORDERS
  • 6.3. OTHERS

7. MARKET BY DRUG CLASS

  • 7.1. CORTICOSTEROIDS
  • 7.2. MONOCLONAL ANTIBODIES
  • 7.3. CALCINEURIN INHIBITORS
  • 7.4. MTOR INHIBITORS
  • 7.5. OTHERS

8. GEOGRAPHICAL ANALYSIS

  • 8.1. EUROPE
    • 8.1.1. UNITED KINGDOM
    • 8.1.2. GERMANY
    • 8.1.3. FRANCE
    • 8.1.4. ITALY
    • 8.1.5. RUSSIA
    • 8.1.6. BELGIUM
    • 8.1.7. POLAND
    • 8.1.8. REST OF EUROPE

9. COMPANY PROFILES

  • 9.1. ABBVIE INC
  • 9.2. ALLERGAN PLC (ACQUIRED BY ABVIE INC)
  • 9.3. ASTELLAS PHARMA INC
  • 9.4. BRISTOL-MYERS SQUIBB COMPANY
  • 9.5. CIPLA LTD
  • 9.6. DR. REDDY'S LABORATORIES LTD
  • 9.7. F HOFFMANN-LA ROCHE AG
  • 9.8. GLAXOSMITHKLINE PLC
  • 9.9. INTAS PHARMACEUTICALS LTD (ACCORD HEALTHCARE LTD)
  • 9.10. JANSSEN PHARMACEUTICALS NV (JHONSON & JHONSON)
  • 9.11. MYLAN NV
  • 9.12. NOVARTIS INTERNATIONAL AG (SANDOZ)
  • 9.13. PFIZER INC
  • 9.14. SANOFI SA
  • 9.15. VELOXIS PHARMACEUTICALS

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - IMMUNOSUPPRESSANT DRUGS
  • TABLE 2: SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
  • TABLE 3: TOP 15 POSITIVE NET EXPORTS COUNTRIES AND NEGATIVE NET EXPORTS FOR DRUGS & MEDICINES COUNTRIES
  • TABLE 4: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 5: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 6: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 7: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 8: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 9: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY CLASS, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 10: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: DEVELOPMENT OF IMMUNOSUPPRESSANT DRUGS
  • FIGURE 2: KEY INVESTMENT INSIGHTS
  • FIGURE 3: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 4: OPPORTUNITY MATRIX
  • FIGURE 5: VENDOR LANDSCAPE
  • FIGURE 6: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2019
  • FIGURE 7: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY HOSPITAL PHARMACIES, 2019-2028 (IN $ MILLION)
  • FIGURE 8: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY RETAIL PHARMACIES, 2019-2028 (IN $ MILLION)
  • FIGURE 9: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY ONLINE PHARMACIES, 2019-2028 (IN $ MILLION)
  • FIGURE 10: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, GROWTH POTENTIAL, BY END-USER, IN 2019
  • FIGURE 11: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY ORGAN TRANSPLANTATION, 2019-2028 (IN $ MILLION)
  • FIGURE 12: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY AUTOIMMUNE DISORDERS, 2019-2028 (IN $ MILLION)
  • FIGURE 13: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
  • FIGURE 14: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, GROWTH POTENTIAL, BY CLASS, IN 2019
  • FIGURE 15: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY CORTICOSTEROIDS, 2019-2028 (IN $ MILLION)
  • FIGURE 16: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY MONOCLONAL ANTIBODIES, 2019-2028 (IN $ MILLION)
  • FIGURE 17: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY CALCINEURIN INHIBITORS, 2019-2028 (IN $ MILLION)
  • FIGURE 18: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY MTOR INHIBITORS, 2019-2028 (IN $ MILLION)
  • FIGURE 19: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
  • FIGURE 20: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, REGIONAL OUTLOOK, 2018 & 2028 (IN %)
  • FIGURE 21: UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 22: GERMANY IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 23: FRANCE IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 24: ITALY IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 25: RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 26: BELGIUM IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 27: POLAND IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 28: REST OF EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
Back to Top